Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer
Medicinal Chemistry Research · 2026-11-02
DOI: 10.1007/s00044-026-03633-3 ↗Abstract
Abstract Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative tumors are the most common types of breast cancer. Mutation of ESR1 complicates their therapy. On September 04, 2026, camizestrant (Etcamah ® ) received approval for HR-positive and HER2-negative, locally advanced or metastatic breast cancer after detecting ESR1 mutation during medication with aromatase and CDK4/6 inhibitors. The mutation was identified through circulating tumor deoxyribonucleic acid, thus representing its first interventional use to guide a therapy switch as part of a clinical study. Camizestrant is a selective estrogen receptor degrader (SERD) and complete antagonist of the estrogen receptor. A dose of 75 mg is taken by mouth once daily concomitantly with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. In a drug regimen comprising an aromatase inhibitor along with a CDK4/6 inhibitor, a significant improvement in progression-free survival was achieved when the aromatase inhibitor was exchanged for camizestrant. This makes camizestrant a next-generation oral SERD for treating advanced breast cancer.
EUVIMED